NNE1 (also known as NNEI, MN-24 and AM-6527) is an
indole-based
synthetic cannabinoid, representing a
molecular hybrid of
APICA and
JWH-018[1] that is an
agonist for the
cannabinoid receptors, with
Ki values of 60.09 nM at
CB1 and 45.298 nM at
CB2 and
EC50 values of 9.481 nM at CB1 and 1.008 nM at CB2.[2] It was invented by
Abbott and has a
CB1 receptor pEC50 of 8.9 with around 80x selectivity over the related
CB2 receptor.[3] It is suspected that metabolic hydrolysis of the amide group of NNE1 may release
1-naphthylamine, a known
carcinogen, given the known metabolic liberation (and presence as an impurity) of
amantadine in the related compound
APINACA, and NNE1 was banned in New Zealand in 2012 as a
temporary class drug to stop it being used as an ingredient in then-legal
synthetic cannabis products.[4] NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.[5]
^Blaazer AR, Lange JH, van der Neut MA, Mulder A, den Boon FS, Werkman TR, et al. (October 2011). "Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity". European Journal of Medicinal Chemistry. 46 (10): 5086–98.
doi:
10.1016/j.ejmech.2011.08.021.
PMID21885167.
^Sasaki C, Saito T, Shinozuka T, Irie W, Murakami C, Maeda K, et al. (January 2015). "A case of death caused by abuse of a synthetic cannabinoid N -1-naphthalenyl-1-pentyl-1H -indole-3-carboxamide". Forensic Toxicology. 33 (1): 165–169.
doi:
10.1007/s11419-014-0246-5.
S2CID13524298.
NNE1 (also known as NNEI, MN-24 and AM-6527) is an
indole-based
synthetic cannabinoid, representing a
molecular hybrid of
APICA and
JWH-018[1] that is an
agonist for the
cannabinoid receptors, with
Ki values of 60.09 nM at
CB1 and 45.298 nM at
CB2 and
EC50 values of 9.481 nM at CB1 and 1.008 nM at CB2.[2] It was invented by
Abbott and has a
CB1 receptor pEC50 of 8.9 with around 80x selectivity over the related
CB2 receptor.[3] It is suspected that metabolic hydrolysis of the amide group of NNE1 may release
1-naphthylamine, a known
carcinogen, given the known metabolic liberation (and presence as an impurity) of
amantadine in the related compound
APINACA, and NNE1 was banned in New Zealand in 2012 as a
temporary class drug to stop it being used as an ingredient in then-legal
synthetic cannabis products.[4] NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.[5]
^Blaazer AR, Lange JH, van der Neut MA, Mulder A, den Boon FS, Werkman TR, et al. (October 2011). "Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity". European Journal of Medicinal Chemistry. 46 (10): 5086–98.
doi:
10.1016/j.ejmech.2011.08.021.
PMID21885167.
^Sasaki C, Saito T, Shinozuka T, Irie W, Murakami C, Maeda K, et al. (January 2015). "A case of death caused by abuse of a synthetic cannabinoid N -1-naphthalenyl-1-pentyl-1H -indole-3-carboxamide". Forensic Toxicology. 33 (1): 165–169.
doi:
10.1007/s11419-014-0246-5.
S2CID13524298.